Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

NCT07145125 · clinicaltrials.gov ↗
COMPLETED
Status
222
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University Hospital, Bordeaux